Skip to content
Disclosery

Patient Square Capital LP

Follow

13F filer, CIK 1819257, MENLO PARK, CA

Patient Square Capital LP reported $277,387,744 across 19 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-11. Its ten largest share positions make up 90% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-007478

Period
2025-06-30
Reported value
$277M
Holdings
19
Top 10 weight
90%
New
3
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ARGXnew+29,000$16M
INSMadded+28,550$2.87M
GERNnew+716,000$1.01M
CDTXnew+15,000$731K
ALLOadded+266,814$301K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LQDAreduced-502,452-$6.26M
BLUEPRINT MEDICINES CORPexited-38,500-$3.41M
NTLAexited-232,781-$1.66M
SLNOexited-18,600-$1.33M
EYPTreduced-129,140-$1.22M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000950123-25-007478, largest first. % of portfolio is the value over $277,387,742, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 12,228,465 shares; 2024Q4: 12,480,000 shares; 2025Q1: 12,480,000 shares; 2025Q2: 12,480,000 shares 12,480,000$141M50.71%0Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 171,704 shares; 2024Q4: 307,167 shares; 2025Q1: 330,250 shares; 2025Q2: 358,800 shares 358,800$36.1M13.02%+28,550Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 29,000 shares 29,000$16M5.76%newTimeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,361,979 shares; 2024Q4: 1,410,331 shares; 2025Q1: 1,481,977 shares; 2025Q2: 1,352,837 shares 1,352,837$12.7M4.59%-129,140Timeline
LQDALIQUIDIA CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 7,182,532 shares; 2024Q4: 1,860,371 shares; 2025Q1: 1,522,452 shares; 2025Q2: 1,020,000 shares 1,020,000$12.7M4.58%-502,452Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 235,498 shares; 2024Q4: 470,919 shares; 2025Q1: 920,199 shares; 2025Q2: 817,699 shares 817,699$7.59M2.74%-102,500Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 824,705 shares; 2024Q4: 878,897 shares; 2025Q1: 878,897 shares; 2025Q2: 868,897 shares 868,897$6.54M2.36%-10,000Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 142,201 shares; 2025Q2: 140,000 shares 140,000$6.11M2.2%-2,201Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 64,900 shares; 2025Q1: 116,362 shares; 2025Q2: 113,462 shares 113,462$5.77M2.08%-2,900Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 32,000 shares; 2025Q1: 154,000 shares; 2025Q2: 154,000 shares 154,000$5.45M1.97%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 90,572 shares; 2024Q4: 224,038 shares; 2025Q1: 253,838 shares; 2025Q2: 245,838 shares 245,838$4.93M1.78%-8,000Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 325,789 shares; 2024Q4: 446,296 shares; 2025Q1: 447,296 shares; 2025Q2: 412,296 shares 412,296$4.7M1.69%-35,000Timeline
AGIOAGIOS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 121,732 shares; 2025Q1: 139,732 shares; 2025Q2: 139,732 shares 139,732$4.65M1.68%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 242,341 shares; 2024Q4: 207,603 shares; 2025Q1: 245,496 shares; 2025Q2: 244,283 shares 244,283$4.3M1.55%-1,213Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 56,400 shares; 2025Q1: 83,000 shares; 2025Q2: 74,000 shares 74,000$3.92M1.41%-9,000Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,489,909 shares; 2025Q1: 2,368,186 shares; 2025Q2: 2,635,000 shares 2,635,000$2.98M1.07%+266,814Timeline
GERNGERON CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,321,268 shares; 2025Q1: not reported; 2025Q2: 716,000 shares 716,000$1.01M0.36%newTimeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 15,000 shares 15,000$731K0.26%newTimeline
VYNEVYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 257,033 shares; 2025Q2: 317,033 shares 317,033$523K0.19%+60,000Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORP38,500$3.41Mshares
NTLAINTELLIA THERAPEUTICS INC232,781$1.66Mshares
SLNOSOLENO THERAPEUTICS INC18,600$1.33Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-007478 base2025-08-11acceptance time not in the bulk data set